Both female-founded and female-led, the two firms share a bold vision: to close the gender wealth gap, rewrite outdated ...
GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the last patient has received the final dose in its Phase 3 clinical study of SPD8, a biosimilar to denosumab for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback